Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

ClinicalTrials.gov ID: NCT04953962

Public ClinicalTrials.gov record NCT04953962. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Randomized, Parallel Group, Phase 2 to Establish the Efficacy and Safety of Combinations of CBP501, Cisplatin, and Nivolumab for ≥3rd Line Treatment of Patients With Exocrine Pancreatic Cancer and WBC <10,000/mm3 at Screening

Study identification

NCT ID
NCT04953962
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
CanBas Co. Ltd.
Industry
Enrollment
36 participants

Conditions and interventions

Interventions

  • CBP501 (16) Drug
  • CBP501 (25) Drug
  • Cisplatin Drug
  • Nivolumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 17, 2021
Primary completion
Apr 13, 2023
Completion
Apr 13, 2023
Last update posted
Aug 14, 2023

2021 – 2023

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Arizona Oncology Associates, PC-HOPE Tucson Arizona 85704
Ochsner Clinic Foundation Los Angeles California 70121
University of Colorado Cancer Center Aurora Colorado 80045
Medical Oncology Hematology Consultants, PA Newark Delaware 19713
Illinois Cancer Specialists Arlington Heights Illinois 60005
University of Michigan hospital Ann Arbor Michigan 48109
Minnesota oncology Hematology, P.A. Minneapolis Minnesota 55404
James D Sanchez Henderson Nevada 89052
Oncology Hematology Care, Inc. Cincinnati Ohio 45245
Texas Oncology-Austin Midtown Austin Texas 78705
Mary Crowley Medical Research Center Dallas Texas 75230
Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas Texas 75246
Texas Oncology-McAllen South Second Street McAllen Texas 78503
Texas Oncology- McKinney McKinney Texas 75071
Texas Oncology-San Antonio Northeast San Antonio Texas 78217
Baylor Scott & White Medical Center Temple Texas 76508
Texas Oncology-Northeast Texas Tyler Texas 75702
Virginia Cancer Specialists, PC Arrington Virginia 22205
Northwest Medical Specialties Tacoma Washington 98405
Northwest Cancer Specialists, P.C. Vancouver Washington 98684

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04953962, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 14, 2023 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04953962 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →